10x Genomics price target lowered to $19 from $21 at Barclays
The Fly

10x Genomics price target lowered to $19 from $21 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $19 from $21 and keeps an Overweight rating on the shares. The company reported a “tough” quarter driven by a commercial reorganization and soft genomics capex environment, the analyst tells investors in a research note. The firm believes this is the trough of the demand environment and says the reorg should start to kick in modestly as genomics capex demand starts to improve.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App